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INTRODUCTION
Small cell carcinoma of the uterine cervix (SMCC), which 
comprises about 2% to 5% of most cervical malignancies, 
tends to be progressive at an early stage, with metastasis 
to distant organs and lymph nodes, and is known to 
have a worse prognosis than squamous cell carcinoma or 
adenocarcinoma of the uterine cervix [1-3]. 
Due to the rarity of SMCC, previously reported studies were 
all conducted in a single institution with a limited number 
of patients with prognostic factors, such as tumor size and 
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stage [4,5], which led to the conclusion that early detection of 
the disease is important.
The Pap test is a screening test initially introduced to clinical 
services by George N. Papanicolau in 1939. It has been 
proved that the test is effective to decreasing the frequency 
and recurrence rate of the invasive cervical cancer as well 
as the mortality rate due to the disease. The Pap test is also 
known to have contributed to prominently cordoning off 
the development of the invasive cervical cancer through 
detecting and treating the cervical intraepithelial neoplasia, 
the very prior stage of the disease [6].
However, in the case of SMCC, the earlier detection rate of 
SMCC was relatively low due to the rare prevalence of the 
disease, a growth pattern downward into the epithelium 
while maintaining a normal epithelium, and the relative tumor 
location at a high endocervical portion [7,8]. In these regards, 
it was often reported that, as a screening test, the Pap test 
for SMCC seemed to be destitute of its diagnostic values and 
effectiveness itself [9-11].
The aim of this study is to review the Severance Hospital 
experience in the patients suffering from the SMCC with a 
review of the literature.
MATERIALS AND METHODS
Twenty-seven patients with small cell carcinoma of the 
uterine cervix were diagnosed and treated at the Severance 
Hospital from November 1991 to January 2010. The clinical 
symptoms and chief complaints of the patients at their first 
clinic visit, age, FIGO clinical stage, and treatment modalities 
were investigated. The FIGO classification system was used 
for the determination of disease stages. The survival rate of 
patients was identified by means of correspondence and 
telephone.
Physical examination, including Pap smears, of patients was 
performed every 3 months after treatment. The abdominal 
and pelvic computed tomography and the magnetic 
resonance imaging were performed every 6 months, and 
the patients were carefully followed up. When recurrence 
was suspected, bone scan and other imaging studies were 
performed, and biopsy was used to confirm the recurrence, 
if necessary. If recurrent disease was confirmed, radiation 
therapy and combination chemotherapy followed. The data 
were analyzed retrospectively based on the available charts 
and obtained from pathology reports.
RESULTS
Twenty-seven patients with small cell carcinoma of the 
uterine cervix were diagnosed between November 1991 and 
January 2010. Among 27 patients, 18 of them (66.7%) showed 
symptoms, including vaginal bleeding, at their first clinic visit, 
and the remaining 9 patients (33.3%) showed abnormal Pap 
smear screening in the process of their routine health check-
up, which were the chief complaints at the first clinic visit. It 
was reported that the median age of the patients were 54 
years (range, 24 to 77 years). Eight of 27 patients were less 
than 45 years old. FIGO stage IIB was the most common stage 
(11 of 27 patients) followed by stage IB (9 of 27 patients). In 
terms of treatment modalities, there were 6 cases (23.1%) 
who received adjuvant radiation therapy or chemotherapy 
after radical hysterectomy. In 17 cases (65.4%), combination 
chemoradiation therapy was performed. Three patients 
(11.5%) received radical hysterectomy following neoadjuvant 
chemotherapy (Table 1).
The 5-year overall survival rate of 21 patients, who could be 
followed up, was 57.2%. During the follow-up after primary 
treatment, 16 cases (59.3%) were reported to be in complete 
remission status. Six patients showed recurrence after 
Table 1. Clinical characteristics of the patients
Characteristics Values
Total number of patients  27
Age (yr), median (range)    54 (24-77)
Age distribution (yr) 
    <45   8 (29.6)
    ≥45 19 (70.4)
Stage  
    IA 0 (0.0)
    IB   9 (33.3)
    IIA 1 (3.7)
    IIB 11 (40.8)
    III   4 (14.8)
    IV 2 (7.4)
Reason for initial clinic visit  
    Abnormal Pap smear screening   9 (33.3)
    Symptoms such as vaginal bleeding 18 (66.7)
Treatment  
    RH+adjuvant RTx or CTx   6 (23.1)
    Chemoradiation Tx 17 (65.4)
    Neoadjuvant CTx+RH+adjuvant Tx   3 (11.5)
Values are presented as number (%) unless otherwise indicated. 
RH: radical hysterectomy, RTx: radiation therapy, CTx: chemotherapy, 
Tx: therapy.Pap smear screening for small cell carcinoma of the uterine cervix
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remission. The mean disease-free interval was 9.2 months 
(range, 6 to 11 months) in the recurrent cases. Recurrence 
sites included the para-aortic lymph nodes (n=3), bone (n=3), 
lung (n=2), neck nodes (n=2), liver (n=1), and brain (n=1) 
(Table 2).
Of 9 patients who showed abnormal Pap smear screening 
results, 2 were diagnosed as squamous cell carcinoma, and 2 
cases as small cell carcinoma on the initial cytologic diagnosis. 
In addition, 2 cases were diagnosed as atypical squamous cells 
of undetermined significance (ASCUS), and 3 cases as high-
grade squamous intraepithelial lesions (HSIL), respectively. 
At the final histologic diagnosis, only one case was identified 
as the mixture of small cell carcinoma and a squamous cell 
component, and 8 cases as small cell carcinoma of the uterine 
cervix. The diagnostic accuracy of the cytologic findings was 
22.2% (Table 3). For 9 patients with abnormal Pap smear 
screening results, there were 5 cases (55.6%) of stage IB, 3 
cases (33.3%) of stage IIB, and 1 case (11.1%) of stage III.
DISCUSSION
The rare prevalence of SMCC makes its diagnosis difficult 
and at the same time decreases the sensitivity of cytologic 
diagnosis. According to Kim et al. [9], the diagnostic accuracy 
of cytologic smears in diagnosing SMCC is low (approximately 
38.5%). In addition, Wang et al. [10] reported that only 46% 
of the patients diagnosed with SMCC were diagnosed as 
having abnormal or malignant growths in cytologic smears, 
and Zhou et al. [11] reported that only 14% were diagnosed 
with abnormal or malignant growths. There was no patient 
diagnosed with SMCC in the cytology smears in both studies. 
In this study, only two of the nine patients with abnormal Pap 
smear results were diagnosed with SMCC, resulting in 22.2% 
in terms of diagnostic accuracy with the cytologic findings.
It is known that SMCC shows a histological finding and 
prognosis that are similar to those of small cell carcinoma of 
the lung. SMCC shows rapid progression and early metastasis 
commonly occurring in the lymph nodes or other organs, 
leading to a 60-82% lymph lumen invasion and a 40-60% 
pelvic lymph node metastasis at the time of diagnosis [12,13]. 
Sheets et al. [14] reported that when surgical treatment 
was conducted on patients with early-stage SMCC, nodal 
Table 3. Clinical features and cytologic findings of the abnormal Pap smear results
Case Initial cytologic Dx Histologic Dx Treatment FIGO stage Follow-up (mo) Recurrence
1 SCC SMCC RH+adjuvant RTx IB NED (129) Para-arotic LN
2 SMCC SMCC Chemoradiation Tx IIB NED (17)
3 ASCUS SMCC Chemoradiation Tx III NED (50) Para-arotic LN+neck LN
4 HSIL SMCC Chemoradiation Tx IB UK (140)
5 ASCUS SMCC RH+adjuvant RTx IB NED (22)
6 HSIL SMCC Chemoradiation Tx IB NED (218)
7 SCC SMCC Chemoradiation Tx IB NED (91)
8 HSIL SMCC Neoadjuvant CTx+
RH+adjuvant Tx
IIB DoD (14) Bone (spine)+neck LN
9 SMCC SCC+SMCC component Chemoradiation Tx IIB NED (79)
Dx: diagnosis, FIGO: International Federation of Obstetrics and Gynecology, SCC: squamous cell carcinoma, SMCC: small cell carcinoma of the 
uterine cervix, RH: radical hysterectomy, RTx: radiation therapy, NED: live with no evidence of disease, LN: lymph node, Tx: therapy, ASCUS: 
atypical squamous cells of undetermined significance, HSIL: high-grade squamous intraepithelial lesion, UK: dead of unknown causes, CTx: 
chemotherapy, DoD: dead of disease.
Table 2. The 5 year overall survival rate and recurrence of the patients  
The 5 year overall survival rate 57.2% (12/21)
Complete remission (CR)  16 (59.3)
Recurrence after CR      6 ( 37.5)
FIGO stage of recurrence cases 
    Stage I    2 (33.3)
    Stage II    2 (33.3)
    Stage III    2 (33.3)
Interval to recurrence (mo), mean (range) 9.2 (6-11)
Sites of recurrence  
    Para-aortic LN 1
    Para-aortic LN+neck LN 1
    Neck LN+bone  1
    Lung+brain 1
    Para-aortic LN+bone+right iliac LN 1
    Liver+lung+bone  1
Values are presented as number (%) unless otherwise indicated. 
FIGO: International Federation of Obstetrics and Gynecology, LN: 
lymph node.Hyun Jong Park, et al.
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metastasis was found in approximately 57% of the patients. 
In addition, Sevin et al. [3] reported that, unlike squamous-
cell carcinoma or adenocarcinoma of the uterine cervix, SMCC 
shows a shallow depth of invasion and a small tumor size, 
yet is an aggressive neoplasm that has a higher incidence of 
lymphovascular space involvement and lymph node metastasis. 
The outcome of SMCC is associated with the disease stage. 
Chan et al. [15] reported that, in the case of an early-stage 
disease, where the disease is limited within the radiation 
field, combined-modality therapy showed approximately 
30% treatment success. On the other hand, in the case of 
an advanced-stage disease, the prognosis was too bad to 
find survivors over two years. Due to the rare prevalence of 
this disease, the number of study specimens seen at a single 
institution was relatively small, and prognostic factors, such 
as the tumor size, LN involvement, and FIGO stage, were 
identified [4,5]. In this study, FIGO stage IIB was the most 
common stage (11 of 27 patients), and the 5-year overall 
survival rate of 21 patients who could be followed up was 
reported to be 57.2%.
As the pathophysiology of SMCC is similar to that of small 
cell carcinoma of the lung (SCLC), SMCC treatment can 
also be deduced from the treatment of SCLC. It has been 
continually reported that, if an anticancer agent that is used 
for the treatment of general uterine cervical cancer is used, 
the survival rate of SMCC patients will be 33%; however, if 
an anticancer agent that is used for the treatment of SCLC 
is used, the survival rate will be 68%, showing a statistically 
significant difference. This suggests that the anticancer 
agent used for the treatment of SCLC can be used for the 
postoperative adjuvant chemotherapy regimen of SMCC 
[12]. In fact, other researchers reported that chemotherapy in 
combination with cisplatin and etoposide, and radiotherapy 
used for the treatment of SCLC, were applied to SMCC 
patients and successfully treated approximately 55% of the 
patients [16]. 
According to a large-scale multicenter retrospective study 
that was conducted involving 68 stage IB-IIA patients who 
underwent surgery, neoadjuvant chemotherapy results 
in the downsizing of a bulky mass into an appropriate 
size for surgery, but had no benefit in the overall survival 
rate. In addition, adjuvant chemoradiation therapy after 
surgery contributed less to the survival rate than adjuvant 
chemotherapy alone. Therefore, it was concluded that, 
for early-stage SMCC, primary radical surgery followed by 
adjuvant chemotherapy should be conducted as a preferable 
treatment modality [17]. 
Although this study suffered from limited case samples, it 
was consistent with the concept that Pap smear screening 
might not be helpful in early diagnosis of SMCC considering 
its low diagnostic accuracy. In the light of its low prevalence, a 
large-scale multicenter prospective study may be required to 
improve its diagnosis and treatment. 
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